Summary
Regeneron Pharmaceuticals, Inc. (REGN) presented its 2010 annual report, highlighting significant progress in its clinical pipeline and strategic collaborations. The company continues to advance its key product candidates, particularly VEGF Trap-Eye for ophthalmologic diseases and ARCALYST® for inflammatory conditions like gout flares. The collaboration with Bayer HealthCare for VEGF Trap-Eye yielded positive Phase 3 results in wet age-related macular degeneration (wet AMD), with regulatory submissions planned for 2011. Similarly, positive Phase 3 data for ARCALYST® in gout prevention provides a pathway for future regulatory filings. The extensive collaboration with sanofi-aventis continues to drive the development of multiple antibody candidates across various therapeutic areas, supported by substantial funding from sanofi-aventis, underscoring a strong partnership for pipeline advancement. Financially, Regeneron reported a net loss for 2010, primarily due to significant investments in research and development. However, collaboration revenue and technology licensing revenue provided substantial financial support, complemented by a strong cash position. The company anticipates continued substantial expenses for R&D and preparations for potential commercialization, emphasizing the critical role of its ongoing collaborations for funding. Investors should note the inherent risks in drug development, including clinical trial outcomes, regulatory approvals, and competitive pressures, as outlined in the 'Risk Factors' section.
Financial Highlights
45 data points| Revenue | $459.07M |
| Cost of Revenue | $2.09M |
| Gross Profit | $456.98M |
| R&D Expenses | $489.25M |
| SG&A Expenses | $65.20M |
| Operating Expenses | $556.55M |
| Operating Income | -$97.47M |
| Interest Expense | $9.12M |
| Net Income | -$104.47M |
| EPS (Basic) | $-1.26 |
| EPS (Diluted) | $-1.26 |
| Shares Outstanding (Basic) | 82.93M |
| Shares Outstanding (Diluted) | 82.93M |
Key Highlights
- 1Regeneron reported positive Phase 3 results for VEGF Trap-Eye in wet Age-Related Macular Degeneration (wet AMD), paving the way for regulatory submissions in 2011 with partner Bayer HealthCare.
- 2ARCALYST® demonstrated positive Phase 3 results in preventing gout flares, supporting future regulatory submissions for this indication.
- 3The company has 11 product candidates in clinical development, including three in late-stage (Phase 3), showcasing a robust pipeline.
- 4Regeneron's strategic collaboration with sanofi-aventis is a major financial and operational driver, funding extensive antibody discovery and development programs, with sanofi-aventis providing significant funding.
- 5The company reported a net loss of $104.5 million for 2010, reflecting substantial investments in research and development, but maintained a strong cash position of $626.9 million.
- 6REGN727, a PCSK9 antibody developed with sanofi-aventis, showed promising LDL cholesterol reduction in early-stage clinical trials.
- 7The REGN475 (NGF Antibody) program was placed on clinical hold by the FDA due to safety concerns identified in other companies' similar programs, highlighting regulatory risks.